Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who have been diagnosed with OAB symptoms at Visit 1 of this study. OAB is defined by the International Urogynecological Association (IUGA)/International Continence Society (ICS) 2010 joint report as urinary urgency, with or without urinary incontinence, usually with frequency and nocturia, with no proven infection or other obvious pathology.~* Patients whose physician has made the decision to prescribe Betmiga® as part of routine clinical practice and who are about to start treatment.~Exclusion Criteria:~* Patients who are currently taking Betmiga®.~* Contraindication(s) as per the Betmiga® Summary of Product Characteristics (SPC).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1. OAB patients taking Betmiga® (Type: None): OAB patients whose physician has made the decision to prescribe Betmiga® as part of routine clinical practice and who are about to start treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).